FGFR inhibitor · small molecule
HMPL-453
1 active trials across 2 of our biomarkers, targeting FGFR1-3. Not approved for any biomarker on marked.bio yet.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| FGFR2 fusion or rearrangement | 1 | 2 | Phase 2/3 |
| FGFR3 alteration (mutation or fusion) | 0 | 1 | – |
Sponsors
Industry sponsors leading active biomarker-selected trials of HMPL-453.
- HUTCHMED 1
Trials
1 of 2 trials shown
-
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
… or cytologically confirmed locally advanced unresectable or metastatic ICC patients with FGFR2 fusions/rearrangements/mutation (applicable to Cohort 1, Cohort 2 Stage II, Cohort 3 and Cohort 4…
FGFR2 fusion or rearrangementAdvanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult
-
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
HMPL-453gemcitabinecisplatintoripalimabdocetaxel
Dose expansion phase: patients with UC, GC/GEJ, or IHCC harboring specific FGFR gene alterations;
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementSolid Tumor
No trials match these filters.